Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Ensley

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Cancer|October 1, 1995
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group studyM Hussain, J Benedetti, R E Smith, et al.
Cancer|December 15, 1991
The incidence and significance of thromboembolic complications in patients with high-grade gliomasR Cheruku, E Tapazoglou, J Ensley, et al.
Archives of Otolaryngology--Head & Neck Surgery|November 14, 2000
Progression of head and neck cancer in an in vitro modelG H Yoo, J Washington, M Piechocki, et al.
Cancer|February 15, 1986
The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapyJ Ensley, J Crissman, J Kish, et al.
Cancer Treatment Reports|July 1, 1987
Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University StudyM Al-Sarraf, B Metch, J Kish, et al.
American Journal of Surgery|October 1, 1984
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancerA Weaver, S Fleming, J Ensley, et al.
Plos One|May 31, 2017
Treatment of AKI in developing and developed countries: An international survey of pediatric dialysis modalitiesRupesh Raina, Abigail M Chauvin, Timothy Bunchman, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 19, 2017
Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment RegimensVinod Krishnappa, Mohit Gupta, Mohamed Elrifai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Neutron radiation enhances cisplatin cytotoxicity independently of apoptosis in human head and neck carcinoma cellsH E Kim, M A Krug, I Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1988
An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancerJ Ensley, J Kish, E Tapazoglou, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Cancer|October 1, 1995
Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group studyM Hussain, J Benedetti, R E Smith, et al.
Cancer|December 15, 1991
The incidence and significance of thromboembolic complications in patients with high-grade gliomasR Cheruku, E Tapazoglou, J Ensley, et al.
Archives of Otolaryngology--Head & Neck Surgery|November 14, 2000
Progression of head and neck cancer in an in vitro modelG H Yoo, J Washington, M Piechocki, et al.
Cancer|February 15, 1986
The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapyJ Ensley, J Crissman, J Kish, et al.
Cancer Treatment Reports|July 1, 1987
Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University StudyM Al-Sarraf, B Metch, J Kish, et al.
American Journal of Surgery|October 1, 1984
Superior clinical response and survival rates with initial bolus of cisplatin and 120 hour infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancerA Weaver, S Fleming, J Ensley, et al.
Plos One|May 31, 2017
Treatment of AKI in developing and developed countries: An international survey of pediatric dialysis modalitiesRupesh Raina, Abigail M Chauvin, Timothy Bunchman, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|December 19, 2017
Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment RegimensVinod Krishnappa, Mohit Gupta, Mohamed Elrifai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Neutron radiation enhances cisplatin cytotoxicity independently of apoptosis in human head and neck carcinoma cellsH E Kim, M A Krug, I Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1988
An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancerJ Ensley, J Kish, E Tapazoglou, et al.
Pageof 3